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A bs tr ac t
Background
Fractures in men are a major health issue, and data on the antifracture efficacy of 
therapies for osteoporosis in men are limited. We studied the effect of zoledronic 
acid on fracture risk among men with osteoporosis.
Methods
In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 
1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 
85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo 
at baseline and at 12 months. Participants received daily calcium and vitamin D 
supplementation. The primary end point was the proportion of participants with one 
or more new morphometric vertebral fractures over a period of 24 months.
Results
The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic 
acid group and 4.9% in the placebo group over the 24-month period, representing 
a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence inter-
val, 0.16 to 0.70; P = 0.002). As compared with men who received placebo, men who 
received zoledronic acid had fewer moderate-to-severe vertebral fractures (P = 0.03) 
and less height loss (P = 0.002). Fewer participants who received zoledronic acid had 
clinical vertebral or nonvertebral fractures, although this difference did not reach 
significance because of the small number of fractures. Bone mineral density was 
higher and bone-turnover markers were lower in the men who received zoledronic 
acid (P<0.05 for both comparisons). Results were similar in men with low serum 
levels of total testosterone. The zoledronic acid and placebo groups did not differ 
significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or 
serious adverse events (25.3% and 25.2%).
Conclusions
Zoledronic acid treatment was associated with a significantly reduced risk of vertebral 
fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials 
.gov number, NCT00439647.)
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Osteoporosis is an important cause of morbidity and mortality among men.1,2 Among persons older than 50 years of age, 
approximately 40% of all osteoporotic fractures 
worldwide occur in men.3 Mortality after osteopo-
rotic fracture is higher among men than among 
women.2,4
Previous studies involving men with osteopo-
rosis have focused on the surrogate outcomes of 
bone mineral density and bone-turnover mark-
ers,5-9 but data from double-blind, randomized 
studies assessing antifracture efficacy are lack-
ing. In addition, given the low awareness of the 
disease,10 the development of guidelines for the 
detection and treatment of osteoporosis in men 
has been limited.11 Hence, there is a need for 
randomized trials of osteoporosis treatment in 
men, with fracture as a primary end point. Men 
at risk for fractures are commonly not identified 
or treated.12
Zoledronic acid (Reclast, Novartis Pharmaceu-
ticals; Aclasta, Novartis Pharma) is a bisphospho-
nate administered intravenously. At a dose of 5 mg 
once a year, it has antifracture efficacy in post-
menopausal women with osteoporosis and posi-
tive effects on bone mineral density in men.13,14 
Our multicenter, randomized, prospective trial as-
sessed the effect of zoledronic acid on the risk of 
vertebral fracture among men with osteoporosis.
Me thods
Participants
Men 50 to 85 years of age who had primary osteo-
porosis or osteoporosis associated with low tes-
tosterone levels were eligible to participate if they 
had a bone mineral density T score of –1.5 or less 
(based on the device-specific reference values for 
men) at the total hip or femoral neck and one to 
three prevalent vertebral fractures of mild or mod-
erate grade, as assessed by means of the modified 
semiquantitative method developed by Genant et 
al.15 Men without fractures were eligible if they 
had a bone mineral density T score of –2.5 or less 
at the total hip, femoral neck, or lumbar spine.
Exclusion criteria included four or more prev-
alent vertebral fractures; a 25-hydroxyvitamin D 
level of less than 15 ng per milliliter (37.4 nmol per 
liter) during screening; baseline renal insufficiency 
(calculated creatinine clearance, <30.0 ml per min-
ute)16; a serum alkaline phosphatase level greater 
than 1.5 times the upper limit of the normal 
range or an aspartate aminotransferase or alanine 
aminotransferase level greater than 3 times the 
upper limit of the normal range; hypercalcemia or 
hypocalcemia; hypersensitivity to bisphosphonates; 
and treatment with strontium ranelate or sodium 
fluoride. Patients who were receiving treatment 
with oral or intravenous bisphosphonates, teripara-
tide, calcitonin, or oral or intravenous glucocor-
ticoids were eligible if the prespecified washout 
criteria were met before randomization. For oral 
bisphosphonates, the washout period was 2 years 
(if used for ≥48 weeks), 1 year (if used for >8 but 
<48 weeks), or 6 months (if used for >2 but ≤8 
weeks); for intravenous bisphosphonates, the wash-
out period was 2 years. For teriparatide or other 
parathyroid hormone therapies, the washout peri-
od was 3 months (if used for ≤1 week). For calci-
tonin, the washout period was 6 months (if used 
for ≥12 weeks) or 3 months (if used for ≥4 but 
<12 weeks). For oral or intravenous glucocorti-
coids, the washout period was 1 year. Additional 
exclusion criteria included the use of testosterone 
within 1 year before randomization, the use 
of an a bol ic steroids or growth hormone within 
6 months before randomization, and treatment 
with any investigational drug or drugs, devices, or 
both within 30 days before randomization; bilat-
eral hip replacement; and active hyperthyroidism, 
primary hyperparathyroidism, or hypoparathyroid-
ism. Use of oral bisphosphonates, parathyroid 
hormone, sodium fluoride, strontium ranelate, 
calcitonin, testosterone, systemic glucocorticoids 
or anabolic steroids, and any investigational thera-
py except the study medication were prohibited 
throughout the trial.
Study Design
This 24-month, randomized, double-blind, pla-
cebo-controlled, parallel-group study was con-
ducted in Europe, South America, Africa, and 
Australia from December 2006 to October 2010. 
Between January 2007 and September 2008, par-
ticipants were randomly assigned in a 1:1 ratio to 
receive zoledronic acid at a dose of 5 mg or pla-
cebo, administered as a 15- to 30-minute intrave-
nous infusion at baseline and month 12. Random-
ization was stratified according to study center and 
was performed with the use of a computer-gener-
ated randomization list. All men received daily 
calcium at a dose of 1000 to 1500 mg (in single 
or divided doses at the investigator’s discretion) 
and vitamin D at a dose of 800 to 1200 IU. All 
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study participants and researchers were unaware of 
the study-drug assignments throughout the trial.
The study was designed and implemented in 
accordance with the Harmonized Tripartite Guide-
line for Good Clinical Practice from the Interna-
tional Conference on Harmonization and the 
Declaration of Helsinki,17 with applicable local 
regulations. The institutional review board at each 
center approved the protocol, and all participants 
provided written informed consent. An external 
data monitoring committee periodically reviewed 
the safety information throughout the study (de-
tails are available in the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org). The study protocol is available at NEJM.org.
The study was designed by representatives of 
the sponsor, Novartis Pharma, in cooperation with 
the first author. Data were analyzed by biostatisti-
cians at PPD UK, who were paid by the sponsor, 
and by representatives of the sponsor. The data 
were reanalyzed and the results were confirmed 
by an independent statistical consultant. The first 
and last authors wrote the first draft of the manu-
script and made the decision to submit the man-
uscript for publication. All authors had access to 
the study data and the clinical study report and 
assume responsibility for the completeness and 
accuracy of the reported data as well as the fidel-
ity of the study to the study protocol. Editorial as-
sistance was provided by an employee of BioSci-
ence Communications who was paid by Novartis.
Study Measurements
Vertebral fractures were assessed by means of 
quantitative vertebral morphometry performed on 
lateral thoracic and lumbar-spine radiographs ob-
tained at baseline and months 12 and 24. An in-
cident vertebral fracture was assessed by means 
of morphometry and defined as a reduction in 
vertebral height of 20% or more and 4 mm or 
more. Body height was measured with the use of 
a stadiometer at screening and months 12 and 
24. Clinical fractures (vertebral and nonvertebral) 
were reported by participants at each visit and were 
verified centrally by means of a radiographic report 
or surgical notes. Only confirmed fractures were 
included in the analysis of time to first clinical 
fracture. Bone mineral density and bone-turnover 
markers were analyzed in a subgroup of 100 or 
more participants. Bone mineral density at the 
lumbar spine, total hip, and femoral neck was 
assessed by means of dual-energy x-ray absorpti-
ometry at baseline and months 6, 12, and 24. Bone-
turnover markers (fasting serum β-C-terminal 
telopeptide of type 1 collagen [β-CTX], bone-
specific alkaline phosphatase [BSAP], and pro-
collagen type I N-terminal propeptide [PINP]) lev-
els were measured at baseline and months 3, 6, 
12, 15, 18, and 24. The serum level of total tes-
tosterone was measured once by means of radio-
immunoassay at baseline.
Adverse events were recorded and coded with 
the use of the Medical Dictionary for Regulatory Activi-
ties system. Events meeting criteria for a maxil-
lofacial adverse event or for cardiac arrhythmia 
classified as a serious adverse event were adjudi-
cated by a committee of independent external 
experts who were unaware of the group assign-
ments. Yearly assessments included laboratory 
tests (hematologic and chemical measurements 
and urinalysis), vital signs, body weight, and 
physical examination, with additional visits for 
renal monitoring 9 to 11 days and 90 days after 
each study-drug administration.
Statistical Analysis
The primary end point was the proportion of men 
with one or more new morphometric vertebral 
fractures over 24 months. Secondary end points 
were the proportion of men with one or more new 
morphometric vertebral fractures over 12 months; 
one or more new moderate-to-severe, or new or 
worsening morphometric vertebral fractures over 
12 and 24 months; a change in height at months 
12 and 24; the time to first clinical fracture (ver-
tebral or nonvertebral); and changes from base-
line in bone mineral density at the lumbar spine, 
total hip, and femoral neck and in bone-turnover 
markers. Overall safety was also assessed as a sec-
ondary objective.
Primary efficacy results were analyzed in the 
modified intention-to-treat population (partici-
pants who underwent baseline and one or more 
post-baseline assessments of the primary efficacy 
variable). For morphometric vertebral fractures, 
between-group differences were evaluated with 
the use of a logistic-regression model, with study 
group, number of baseline vertebral fractures (0, 
1, or ≥2), and geographic region as explanatory 
variables. P values were calculated with a likeli-
hood-ratio test. Relative risks and 95% confidence 
intervals were calculated by means of the two-
by-two table method with the use of log-normal 
approximation. Binary variables were used for 
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morphometric vertebral fracture, and in the case 
of missing data on fracture status at 24 months, 
the data were imputed with the use of the last-
observation-carried-forward method. If a month 
12 radiograph was missing and the month 24 ra-
diograph showed no fracture, it was assumed 
there was no fracture at month 12. Clinical frac-
ture was analyzed with the use of the Cox pro-
portional-hazards method in the intention-to-
treat population. Bayesian analyses were also 
performed for clinical and nonvertebral fractures 
on the basis of data from the Health Outcomes 
and Reduced Incidence with Zoledronic Acid Once 
Yearly (HORIZON) Pivotal Fracture Trial13 and the 
HORIZON Recurrent Fracture Trial.14 Log hazard 
ratios from each study were combined with the use 
of the inverse-variance meta-analysis method. The 
meta-analysis mean was used as the prior mean. 
The prior variance was the meta-analysis mean 
variance plus a between-trial variance to discount 
the historical data.18 The 95% credible interval was 
based on the equal-tail method.
Changes in bone mineral density were ana-
lyzed with the use of an analysis of covariance 
(ANCOVA) model with treatment and baseline val-
ues as explanatory variables. Changes in height 
were compared with the use of an ANCOVA model 
with treatment, geographic region, and baseline 
values as explanatory variables. Changes in bone-
turnover markers were compared with the use of 
an ANCOVA model based on the log ratio of the 
post-baseline value to the baseline value, with 
treatment and log baseline values as explanatory 
variables. Within-group analyses of changes from 
baseline in bone-turnover markers were based on 
the least-squares means. The unadjusted mean 
percentage change was plotted over time for each 
bone-turnover marker.
Subgroup analyses of the fracture, bone min-
eral density, and bone-turnover marker end points 
1199 Patients underwent randomization
588 Were assigned to receive
zoledronic acid
611 Were assigned to receive placebo
58 (9.9%) Discontinued study
25 (4.3%) Withdrew consent
15 (2.6%) Died
11 (1.9%) Had adverse event
4 (0.7%) Were lost to
follow-up
3 (0.5%) Had protocol
deviation
35 (6.0%) Did not have baseline
assessment and at least
one assessment of the
primary efficacy variable
after baseline
71 (11.6%) Discontinued study
22 (3.6%) Withdrew consent
18 (2.9%) Died
11 (1.8%) Had adverse event
12 (2.0%) Were lost to
follow-up
4 (0.7%) Had protocol
deviation
4 (0.7%) Had unsatisfactory
therapeutic effects
37 (6.1%)  Did not have baseline
assessment and at least
one assessment of the
primary efficacy variable
after baseline
588 Were included in the ITT population
588 Were included in the safety population
611 Were included in the ITT population
611 Were included in the safety population
530 (90.1%) Completed study
553 (94.0%) Were included in the modified
ITT population
540 (88.4%) Completed study
574 (93.9%) Were included in the modified
ITT population
Figure 1. Enrollment, Randomization, and Outcomes.
ITT denotes intention to treat.
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according to serum levels of total testosterone, 
with the use of thresholds at 350 ng per deciliter 
(12.1 nmol per liter) and 230 ng per deciliter 
(8.0 nmol per liter) based on published recom-
mendations for testosterone substitution,19 were 
performed with the use of the same model as 
that used for the overall analyses. Only partici-
pants with total testosterone measurements per-
formed by noon were included in this analysis. 
The interference of the total testosterone level with 
the effect of zoledronic acid was evaluated with the 
use of an additional interaction term for study 
treatment and total testosterone level.
The study had 90% power to detect a 65% 
reduction in new morphometric vertebral frac-
tures over the 24-month period at a two-sided 
5% significance level, assuming a 7.7% incidence 
rate in the placebo group. The safety population 
included all participants who received one or more 
doses of the study drug.
R esult s
Study Participants
In total, 588 men were randomly assigned to zole-
dronic acid, and 611 men were randomly assigned 
to placebo (Fig. 1); 58 men (9.9%) and 71 men 
(11.6%) in the two groups, respectively, discon-
tinued the study. The modified intention-to-treat 
population comprised a total of 553 men who re-
ceived zoledronic acid and 574 men who received 
placebo; these patients underwent baseline assess-
ments and one or more post-baseline assessments 
of the primary efficacy variable. Fifty-two men who 
received zoledronic acid (8.8%) and 53 men who 
received placebo (8.7%) did not receive the sec-
ond infusion.
Baseline characteristics were similar between 
the groups (Table 1). Total testosterone measure-
ments were available for 495 participants who re-
ceived zoledronic acid and 516 participants who 
received placebo. A total of 116 men who received 
zoledronic acid (23.4%) and 149 men who re-
ceived placebo (28.9%) had a total testosterone 
level of 350 ng per deciliter or less; a small pro-
portion of men in the two groups combined (5.4%) 
had levels of 230 ng per deciliter or less. Baseline 
bone mineral density and bone-turnover marker 
levels were similar across all subgroups of total 
testosterone levels (Table S1 in the Supplemen-
tary Appendix); results with the use of 230 ng per 
deciliter as the threshold were similar to those 
Table 1. Baseline Characteristics of the Patients in the Intention-to-Treat 
Population.*
Variable
Zoledronic Acid 
(N = 588)
Placebo  
(N = 611)
Race — no. (%)†
White 555 (94.4) 578 (94.6)
Black 5 (0.9) 3 (0.5)
Asian 2 (0.3) 0 (0.0)
Other 26 (4.4) 30 (4.9)
Age
Median — yr 66 66
Range — yr 50–85 50–85
Group — no. (%)
<65 yr 260 (44.2) 284 (46.5)
65 to <75 yr 226 (38.4) 213 (34.9)
≥75 yr 102 (17.3) 114 (18.7)
Region — no. (%)
Africa and Latin America 107 (18.2) 107 (17.5)
Central and Eastern Europe 151 (25.7) 161 (26.4)
Northern Europe 101 (17.2) 112 (18.3)
Western and Southern Europe and Oceania 229 (38.9) 231 (37.8)
Total testosterone‡
Mean — ng/dl 451±145.9 439±150.3
≤230 ng/dl — no./total no. (%) 23/495 (4.6) 32/516 (6.2)
>230–350 ng/dl — no./total no. (%) 93/495 (18.8) 117/516 (22.7)
>350 ng/dl — no./total no. (%) 379/495 (76.6) 367/516 (71.1)
Hypogonadism — no. (%) 2 (0.3) 1 (0.2)
Bone mineral density T score§
Femoral neck −2.23±0.677 −2.24±0.685
Total hip −1.70±0.764 −1.72±0.808
Vertebral fractures — no. (%)
0 404 (68.7) 409 (66.9)
1 114 (19.4) 135 (22.1)
≥2 69 (11.7) 66 (10.8)
Osteoporosis medications used before the first 
infusion in the study — no. (%)¶
11 (1.9) 8 (1.3)
Bisphosphonates 8 (1.4) 7 (1.1)
Calcitonin 4 (0.7) 1 (0.2)
* Plus–minus values are means ±SD. There were no significant differences be-
tween the groups. To convert values for total testosterone to nanomoles per 
liter, multiply by 0.0347.
† Race was self-reported.
‡ Data are for all patients with baseline total testosterone measurements that 
were performed by noon.
§ Data are for 586 patients in the zoledronic acid group and 608 patients in the 
placebo group who had baseline bone mineral density measurements.
¶ A patient who had received multiple medications within the same category 
was counted only once. One patient in the zoledronic acid group received 
both calcitonin and bisphosphonate therapies before the first infusion.
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with the use of 350 ng per deciliter (Tables S2, 
S3, and S4 in the Supplementary Appendix).
Fractures
A total of 30 of 553 men in the zoledronic acid 
group (5.4%) and 40 of 574 men in the placebo 
group (7.0%) had radiographs that could be eval-
uated at month 12 but not at month 24; 4 men 
(0.7%) and 3 men (0.5%), respectively, had radio-
graphs that could be evaluated at month 24 only; 
the remaining patients had radiographs that could 
be evaluated at both time points. A significantly 
lower proportion of men in the zoledronic acid 
group (1.6%) had one or more new morphometric 
vertebral fractures over 24 months, as compared 
with men in the placebo group (4.9%) (Fig. 2), 
corresponding to an absolute risk reduction of 3.3 
percentage points and a relative risk reduction of 
67% (P = 0.002). Sensitivity analyses with the use of 
data on patients for whom results of radiography at 
month 24 were available, single imputation, and 
multiple imputation had similar results (Table S5 
in the Supplementary Appendix). A 68% reduction 
in the relative risk of new morphometric vertebral 
fractures with zoledronic acid was apparent at month 
12 (P = 0.02) (Fig. 2, and Table S6A in the Supple-
mentary Appendix). The total testosterone level did 
not affect the antifracture efficacy of zoledronic 
acid (P>0.80 for interaction). Among men with 
serum total testosterone levels of 350 ng per deci-
liter or less, zoledronic acid was associated with a 
nonsignificant 67% reduction in the relative risk 
of new morphometric vertebral fractures (P = 0.13) 
(Table S2 in the Supplementary Appendix).
Significantly fewer men who received zole-
dronic acid than men who received placebo had 
one or more new moderate-to-severe morphomet-
ric vertebral fractures, both at month 12 (relative 
risk reduction, 81%; P = 0.01) and at month 24 
(relative risk reduction, 63%; P = 0.03). Similar re-
sults were seen for new or worsening morphomet-
ric vertebral fractures at month 12 (relative risk 
reduction, 55%; P = 0.07) and month 24 (relative 
risk reduction, 59%; P = 0.007). Changes in height 
(least-squares mean) from baseline were −0.8 and 
−2.5 mm at month 12 (P = 0.008) and −2.2 and 
−4.5 mm at month 24 (P = 0.002) in the zole-
dronic acid and placebo groups, respectively.
Six men who received zoledronic acid (1.0%) 
and 11 men who received placebo (1.8%) had one 
or more clinical vertebral or nonvertebral frac-
tures during the study (Table S6B in the Supple-
mentary Appendix), but the between-group dif-
ference was not significant. With the use of the 
observed effects in the HORIZON studies,13,14 
Bayesian analyses suggested that zoledronic acid 
may reduce the risk of clinical fractures among 
men (Table S6C in the Supplementary Appendix).
Bone Density
As compared with placebo, zoledronic acid was 
associated with significant and sustained in-
creases in bone mineral density at the lumbar 
spine, total hip, and femoral neck over a 24-month 
period (P<0.05 for all comparisons) (Fig. 3, and 
Fig. S1A and S1B in the Supplementary Appen-
dix). The effect of zoledronic acid on bone min-
eral density was similar in men with total testos-
terone levels of more than 350 ng per deciliter 
and in men with levels of 350 ng per deciliter or 
less (P>0.40 for interaction) (Table S3 in the Sup-
plementary Appendix).
Biochemical Markers
Serum β-CTX, PINP, and BSAP levels were lower 
in men who received zoledronic acid than in men 
who received placebo at all time points measured 
(P<0.001 for all comparisons) (Fig. 3, and Fig. S1C 
in the Supplementary Appendix). A similar pat-
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Figure 2. Relative Risks of One or More New Morphometric Vertebral 
Fractures in the Modified Intention-to-Treat Population.
The relative risk was calculated on the basis of a two-by-two table, and the 
normal approximation was used to calculate the 95% confidence interval 
(CI). A relative risk of less than 1 implies that the likelihood of the event is 
lower with zoledronic acid than with placebo.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAETSBIBLIOTHEK BERN on December 3, 2018. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;18 nejm.org november 1, 20121720
tern was seen in urinary N-terminal telopeptide 
levels (P<0.001 for all comparisons). The effect of 
zoledronic acid on bone-turnover markers was 
generally similar in men with total testosterone 
levels of more than 350 ng per deciliter and those 
with levels of 350 ng per deciliter or less (P>0.10 
for interaction at months 12 and 24) (Table S4 in 
the Supplementary Appendix), with the exception 
of PINP, for which the reduction was significant-
ly less in the subgroup of men with total testos-
terone levels of 350 ng per deciliter or less than in 
the subgroup with levels of more than 350 ng per 
deciliter (P<0.02).
Safety
No significant differences were observed between 
the two groups with respect to deaths or serious 
adverse events, with the exception of any myocar-
dial infarction (in nine men [1.5%] in the zole-
dronic acid group and two [0.3%] in the placebo 
group, [P = 0.03]; none of the events were consid-
ered by the investigator to be related to the study 
drug) (Table 2). There were 31 cardiac serious ad-
verse events in the zoledronic group (5.3%) and 
30 in the placebo group (4.9%) (P = 0.79). Men who 
received zoledronic acid reported more adverse 
events of pyrexia, myalgia, arthralgia, headaches, 
chills, pain in the extremities, and influenza-like 
symptoms. There were no significant differences 
between the groups in the incidence of atrial fi-
brillation, cardiac arrhythmias, or renal dysfunc-
tion. No cases of osteonecrosis of the jaw were 
observed. Two men in the zoledronic acid group 
and one man in the placebo group had hip frac-
tures during the study, but none were atypical or 
subtrochanteric.
Discussion
Over a 2-year period, two annual infusions of 
zoledronic acid significantly reduced the risk of 
new morphometric vertebral fractures by 67% 
among men with osteoporosis. This reduction 
was similar to that reported in postmenopausal 
women with osteoporosis who received zole-
dronic acid (relative reduction in the risk of ver-
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Figure 3. Percentage Change in Bone Mineral Density 
and Biochemical Markers over Time.
Results are shown for bone mineral density at the lumbar 
spine (Panel A), serum β-C-terminal telopeptide of 
type 1 collagen (β-CTX) (Panel B), and procollagen 
type I N-terminal propeptide (PINP) (Panel C) in a 
subgroup of patients. The asterisk denotes P<0.05 for 
the comparison with the baseline value, and the single 
dagger P<0.001 for the between-group comparison. 
Zoledronic acid or placebo was administered at months 
0 and 12. The error bars represent standard errors of 
the mean. In Panels B and C, the values shown are 
based on unadjusted mean percentage changes.
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tebral fracture, 71% at 2 years),13 suggesting that 
the antifracture effect of zoledronic acid is inde-
pendent of sex. Zoledronic acid therapy had an 
acceptable safety profile. These results provide 
support for the value of antiresorptive therapy in 
men with osteoporosis.
Our study showed that zoledronic acid reduced 
the risk of height loss and moderate-to-severe 
vertebral fractures, which are associated with an 
increased risk of subsequent vertebral and non-
vertebral fractures.20-23 Although the power of the 
study to detect a reduction in the risk of nonver-
tebral fracture was modest, rates of nonvertebral 
fracture were consistently lower among men who 
received zoledronic acid than among those who 
received placebo, and the point estimates were 
Table 2. Adverse Events in the Safety Population.*
Event
Zoledronic Acid 
(N = 588)
Placebo 
(N = 611) P Value†
no. of patients (%)
General
Any adverse event 534 (90.8) 466 (76.3) <0.001
Any serious adverse event 149 (25.3) 154 (25.2)
Death 15 (2.6) 18 (2.9)
Five most common adverse events in zoledronic acid group
Pyrexia 143 (24.3) 23 (3.8) <0.001
Myalgia 129 (21.9) 25 (4.1) <0.001
Arthralgia 123 (20.9) 68 (11.1) <0.001
Back pain 84 (14.3) 74 (12.1)
Headache 82 (13.9) 27 (4.4) <0.001
Renal event
Increase from baseline in serum creatinine >0.5 mg/dl  
any time during study‡
14 (2.4) 18 (3.0)
Urinary protein on dipstick analysis, >2+§ 1 (0.2) 1 (0.2)
Creatinine clearance <30 ml/min at any time during study¶ 3 (0.5) 9 (1.6)
Cardiac or cardiovascular event
Hypertension
Adverse event 50 (8.5) 46 (7.5)
Serious adverse event 3 (0.5) 3 (0.5)
Cardiac disorder, serious adverse event 31 (5.3) 30 (4.9)
Atrial fibrillation, serious adverse event 7 (1.2) 5 (0.8)
Angina pectoris, serious adverse event 6 (1.0) 7 (1.1)
Myocardial infarction
Any, serious adverse event 9 (1.5) 2 (0.3) <0.05
Acute, serious adverse event 5 (0.9) 1 (0.2)
Serious adverse event 4 (0.7) 1 (0.2)
Cardiac failure, serious adverse event 1 (0.2) 4 (0.7)
* A participant with multiple occurrences of an adverse event within a preferred term (according to codes used in the 
Medical Dictionary for Regulatory Activities) was counted only once.
† P values are based on Fisher’s exact test.
‡ A total of 584 patients in the zoledronic acid group and 610 patients in the placebo group had serum creatinine mea-
surements that could be evaluated at both baseline and one or more time points after the baseline visit.
§ A total of 556 patients in the zoledronic acid group and 572 patients in the placebo group had urinary protein measure-
ments that could be evaluated at both baseline and one or more time points after the baseline visit.
¶ A total of 557 patients in the zoledronic acid group and 577 patients in the placebo group had creatinine clearance 
measurements that could be evaluated at both baseline and one or more time points after the baseline visit. Creatinine 
clearance was calculated with the use of the Cockroft–Gault formula.16
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAETSBIBLIOTHEK BERN on December 3, 2018. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;18 nejm.org november 1, 20121722
similar to the significant risk reductions in larger 
studies involving women.13
Zoledronic acid significantly improved bone 
mineral density and reduced bone-turnover mark-
ers, with changes from baseline that were simi-
lar to those reported for other bisphosphonates in 
men with osteoporosis6-9 and were consistent with 
those seen in postmenopausal women with os-
teoporosis receiving bisphosphonates (including 
zoledronic acid).13,24,25 Previous studies of bisphos-
phonates in men with osteoporosis have consis-
tently revealed beneficial effects on bone mineral 
density and bone-turnover markers, but they were 
not primarily designed to assess the effects on 
fractures.6-9 For example, alendronate lowered the 
incidence of morphometric vertebral fractures (a 
secondary end point) in men in a 2-year double-
blind trial involving 241 patients, but the number 
of fractures was small.7 Since clinical data show-
ing a reduction in the risk of fracture among men 
with osteoporosis have been lacking, our study was 
designed to be placebo-controlled. We believed 
that clinical equipoise existed and that a positive 
result would probably improve care for men with 
osteoporosis. Recently, denosumab was shown to 
reduce the risk of vertebral fracture (a secondary 
end point) among men receiving androgen-depri-
vation therapy for nonmetastatic prostate can-
cer.26,27 Our data provide further support for the 
precept that antiresorptive treatments are effec-
tive in both men and women.
In our study, zoledronic acid had similar ben-
eficial effects on fractures and bone mineral den-
sity in men with low testosterone levels and men 
with normal levels. However, few men had total 
testosterone levels that were low enough (<230 ng 
per deciliter) to benefit from testosterone treat-
ment,19 making it difficult to draw conclusions 
about the effect of zoledronic acid in this popu-
lation. Furthermore, because the randomization 
was not stratified according to total testosterone 
level, the numbers of patients with low levels in 
the two groups were different.
Despite the fact that current public health ef-
forts to detect osteoporosis and prevent fractures 
in men are inadequate,28 the ability to establish 
detection and treatment recommendations has 
been limited because of the absence of unambigu-
ous evidence of effective antifracture therapies 
in men.11 Although our findings with zoledronic 
acid do not imply that all data on drugs for osteo-
porosis in women can be extrapolated to men, our 
study should provide the confidence to proceed.
A key strength of this study was a study popu-
lation that was sufficiently large to detect an 
effect of treatment on the risk of vertebral frac-
ture. However, the study was not powered to ad-
dress the effect of zoledronic acid on nonvertebral 
(including hip) fractures. For ethical reasons, men 
with multiple or severe vertebral fractures were not 
enrolled, and the patient population was relatively 
young. The significant difference that we observed 
in the incidence of myocardial infarction between 
the groups has not previously been observed with 
zoledronic acid,13,14 and any causality or associa-
tion with zoledronic acid is unknown.
In conclusion, our prospective study that as-
sessed fractures as the primary end point in men 
with osteoporosis showed that over a 2-year period, 
a once-yearly infusion of zoledronic acid at a dose 
of 5 mg was associated with a significant decrease 
in the risk of new vertebral fractures.
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